Amir Faridmoayer, PhD, Co-Founder & Vice President Discovery, LimmaTech Biologics AG
Amir obtained his PhD in 2005 from the University of British Columbia, followed by Post-Doctoral fellowships at the Alberta Glycomic Center, University of Alberta (Canada) and the Institute of Microbiology at the Swiss Federal Institute of Technology (ETH Zurich). He has over 10 years’ experience in the field of Glycobiology and, during his research, has established a novel bacterial glycoengineering platform for production of different vaccine candidates. He joined the management team of GlycoVaxyn AG in 2013 and established the Discovery department where he was responsible for the development of proprietary research projects and platforms development. After the acquisition of GlycoVaxyn by GSK in February 2015, he co-founded LimmaTech Biologics AG. As Vice President Discovery at LimmaTech, Amir is responsible for the development of early stage vaccine in collaboration with GSK and novel glycoengineering platforms for the production of therapeutic proteins.